Kiniksa Pharmaceuticals International, plc
KNSA
株式のランク
#2912
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
株価
$82.30
時価総額
$6.42B
変化（1日）
3.55%
変化（1年）
111.08%
国
GB
取引 Kiniksa Pharmaceuticals International, plc (KNSA)
カテゴリー
Healthcare
Kiniksa Pharmaceuticals International, plc（KNSA）のP/S比率
October 2026 時点のP/S比率 TTM: 7.32
Kiniksa Pharmaceuticals International, plc の最新の財務報告および株価によると、現在のP/S比率（TTM）は 7.32 です。2023 年末時点でのP/S比率は 4.55 でした。
Kiniksa Pharmaceuticals International, plc の P/S 比率の履歴（2016 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 7.32 | 119.03% |
| 2024 | 3.34 | -26.59% |
| 2023 | 4.55 | -3.68% |
| 2022 | 4.72 | -77.46% |
| 2021 | 20.94 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.31 | 40.94% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 106.72% |
US
|
